KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma.

Meletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S Vincent Rajkumar

Blood Cancer J 16(1) 15

PMID41345095
PMCIDPMC12808303
DOI10.1038/s41408-025-01411-9
发表日期2025-12-04
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

TOURMALINE-MM3 (NCT02181413) and -MM4 (NCT02312258) were phase 3 studies of fixed-duration, single-agent ixazomib maintenance in post-transplant (TOURMALINE-MM3)/transplant-ineligible (TOURMALINE-MM4) patients with newly diagnosed multiple myeloma (NDMM) that demonstrated improved median progression-free survival (PFS) for ixazomib vs placebo. We present the final overall survival (OS) analyses for each study separately. In both studies, eligible patients were randomized 3:2 to receive ixazomib maintenance (3 mg [cycles 1-4], 4 mg [from cycle 5 if tolerated]) or matching placebo for ≤26 cycles, or until progressive disease/unacceptable toxicity. At median follow-up of approximately 8 years (TOURMALINE-MM3) and 5 years (TOURMALINE-MM4), median OS was not reached in either arm in MM3 (hazard ratio [HR], 1.025; 95% confidence interval [CI], 0.789-1.332; p = 0.850), and was 64.8 (ixazomib) vs 69.5 (placebo) months in MM4 (HR, 1.090; 95% CI, 0.861-1.381; p = 0.473). No new safety signals were identified in either study; incidence of new primary malignancies was low. Despite meeting their primary endpoints (PFS), neither final OS analysis of TOURMALINE-MM3/-MM4 showed statistically significant differences between fixed-duration ixazomib maintenance and placebo in patients with NDMM. The growing number of available, highly effective salvage treatments with novel mechanisms of action make demonstrating an OS advantage in front-line myeloma studies increasingly challenging.

KM 提取结果

5 个 Figure · 10 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Kaplan–Meier analysis of overall survival (ITT population). A TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, HR hazard ratio, NR not reached, OS overall survival.

A

overall survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
B

overall survival

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Fig. 4

Kaplan–Meier analysis of time to next treatment (ITT population). A TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, HR hazard ratio, ITT intention-to-treat, OS overall survival.

A

time to next treatment

Fig. 4 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

time to next treatment

Fig. 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Fig. 5

Progression-free survival in next-line therapy (ITT population). A TOURMALINE-MM3 study. B TOURMALINE MM4 study. CI confidence interval, HR hazard ratio, ITT intention-to-treat, OS overall survival.

A

Progression-free survival 2

Fig. 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival 2

Fig. 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Fig. 6

Kaplan–Meier analysis of overall survival in patients who received a proteasome inhibitor as next-line therapy. A and TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, HR hazard ratio, OS overall survival.

A

overall survival

Fig. 6 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:off origin start
查看结果
B

overall survival

Fig. 6 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:flat topline artifact
查看结果
KM Figure2 个面板

Fig. 7

Kaplan–Meier analysis of overall survival in patients whose next-line therapy did not include a proteasome inhibitor. A TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, HR hazard ratio, OS overall survival.

A

overall survival

Fig. 7 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:flat topline artifact
查看结果
B

overall survival

Fig. 7 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Disposition of patients during the TOURMALINE-MM3 and TOURMALINE-MM4 studies. *Two patients in the ixazomib arm did not receive the allocated treatment (one patient withdrew, and the other one did not meet the inclusion criteria due to a low platelet count) [ 9 ]. † One patient in the placebo arm did not receive the allocated treatment due to patient withdrawal [ 9 ]. AE adverse event, FU follow-up, ITT intent-to-treat, PD progressive disease, Pt patient.
非 KM Figure
Fig. 3Overall survival in patient subgroups (ITT population). A TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, CR complete response, HR hazard ratio, ISS International Staging System, ITT intention-to-treat, MRD minimal residual disease, NE not estimable, PI proteasome inhibitor, PR partial response, VGPR very good partial response.
非 KM Figure